Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysterosalpingography Practice
Phase 4
- Conditions
- Gynecological Pathology
- Interventions
- Drug: Lidocaine-Prilocaine creamDrug: placebo
- Registration Number
- NCT01303614
- Lead Sponsor
- Consorci Sanitari de Terrassa
- Brief Summary
The purpose of this study is to demonstrate that Lidocaine-Prilocaine cream decrease pain during hysterosalpingography diagnostic practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- patients that must perform a hysterosalpingography
- acceptance to participate in the study signed informed consent
Exclusion Criteria
- hypersensitivity or allergy to anesthetics
- refusal of the patient
- patients under age 18 years old and pregnant
- unbearable pain that involves other analgesic measures
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Lidocaine-Prilocaine cream Lidocaine-Prilocaine cream - Placebo placebo purified water, ethylene glycol stearate, palm, palm stearate, polyethylene glycol, liquid paraffin, benzoic acid
- Primary Outcome Measures
Name Time Method pain reduction in the performance of hysterosalpingography after hysterosalpingography and a month later decrease in pain inmediately after the completion of hysterosalpingography and one month after completion of the diagnostic test by an analogue pain scale.
- Secondary Outcome Measures
Name Time Method sense of discomfort experience during the procedure a month after hysterosalpingography willingness to repeat the diagnostic technique
Trial Locations
- Locations (1)
Consorci Sanitari de Terrassa
🇪🇸Terrassa, Barcelona, Spain